34.1 Acute Infectious Diarrhea & Gastroenteritis

Definitions & Temporal Staging of Diarrhea

Diarrhea is clinically defined as the passage of three or more loose, unformed, or liquid stools per day, or a daily stool output exceeding 200 grams. In ambulatory family medicine, establishing the precise duration of symptoms is the critical first branching point in clinical decision-making, guiding the threshold for diagnostic testing versus supportive observation.

Chronological Staging

1. Acute Diarrhea (<14 Days Duration):
   • Predominantly infectious in origin (viruses, bacteria, protozoa) or related to acute foodborne enterotoxin ingestion, acute medication initiation, or dietary indiscretion.
   • The vast majority of episodes in immunocompetent hosts are self-limited, resolving within 3 to 7 days without requiring diagnostic stool testing or antimicrobial therapy.
2. Persistent Diarrhea (14 to 30 Days Duration):
   • Frequently caused by persistent protozoal infections (Giardia duodenalis, Cryptosporidium, Cystoisospora belli), post-infectious disaccharidase (lactase) deficiency, or post-infectious irritable bowel syndrome (PI-IBS).
   • Merits targeted diagnostic evaluation, including microscopic examination for ova and parasites (O&P) and selective stool antigen or molecular assays.
3. Chronic Diarrhea (>30 Days Duration):
   • Non-infectious etiologies predominate, including inflammatory bowel disease (IBD; ulcerative colitis, Crohn disease), celiac disease, microscopic colitis, irritable bowel syndrome (IBS-D), malabsorption syndromes, chronic medication side effects, or neuroendocrine neoplasms.

---

Non-Inflammatory (Watery) vs. Inflammatory (Dysenteric) Diarrhea

Infectious gastroenteritis falls into two major pathophysiological categories based on anatomical localization, mucosal invasion, and inflammatory response.

Clinical and Pathophysiologic Comparison

---

Incubation Windows, Exposure History & Pathogen Profiles

A detailed dietary and exposure history provides high-yield diagnostic clues before laboratory confirmation is available.

                    INCUBATION WINDOWS & FOOD EXPOSURES

     [1 to 6 Hours]  ─────────> Pre-formed Enterotoxin Ingestion
                                • Staphylococcus aureus (mayonnaise, dairy, meats)
                                • Bacillus cereus emetic toxin (fried rice)
                                • Intense emesis, minimal or no fever

     [8 to 16 Hours] ─────────> Ingested Inoculum Toxins (In Vivo Production)
                                • Clostridium perfringens (buffet meats, gravies)
                                • Bacillus cereus diarrheal toxin (vegetables, meats)
                                • Moderate watery diarrhea, crampy periumbilical pain

     [16 to 72 Hours] ────────> Bacterial Multiplication & Mucosal Action
                                • ETEC (Traveler's diarrhea: contaminated water/produce)
                                • Salmonella (poultry, raw eggs, reptiles, pet turtles)
                                • Campylobacter jejuni (undercooked chicken, unpasteurized milk)
                                • Shigella (person-to-person, daycares; very low inoculum)

     [2 to 8 Days]   ─────────> Invasive / Cytotoxic Manifestations
                                • STEC (E. coli O157:H7: undercooked beef, leafy greens)
                                • Yersinia enterocolitica (pork chitterlings; pseudoappendicitis)
                                • Cryptosporidium / Giardia (untreated water, public pools)

Key Pathogens Encountered in Family Medicine

• Norovirus: The leading cause of acute gastroenteritis outbreaks across all age groups worldwide. Highly contagious (infectious dose <20 virions) and spread via vomiting aerosols, direct person-to-person contact, and contaminated fomites or shellfish. Characterized by sudden, explosive projectile vomiting, concurrent watery diarrhea, and low-grade fevers in closed communities (cruise ships, schools, nursing homes, hospitals). Resolves spontaneously within 24 to 48 hours.
• Rotavirus: Historically the most common cause of severe, dehydrating infantile gastroenteritis before widespread implementation of the live oral rotavirus vaccine (administered at 2, 4, and 6 months of age). Produces significant vomiting followed by copious watery diarrhea and rapid volume depletion in children aged 6 to 24 months.
• Campylobacter jejuni: Most common bacterial cause of gastroenteritis in developed nations. Acquired from undercooked poultry or unpasteurized dairy. Manifests with high fevers, rigors, periumbilical pain, and bloody stools. Notably causes pseudoappendicitis (acute right lower quadrant pain and mesenteric adenitis mimicking appendicitis). Recognized as the leading antecedent infectious trigger for Guillain-Barré syndrome (via molecular mimicry between Campylobacter lipooligosaccharides and human peripheral nerve gangliosides GM1) and reactive arthritis (HLA-B27).
• Non-Typhoidal Salmonella enterica: Transmitted via undercooked eggs, poultry, contaminated produce, and exotic pets (reptiles, amphibians, turtles). Causes inflammatory diarrhea with fever, cramps, and bacteremia risk. Routine antibiotic therapy in uncomplicated immunocompetent hosts is contraindicated because it prolongs fecal bacterial shedding and does not shorten symptom duration. Antibiotics (oral ciprofloxacin or azithromycin, or IV ceftriaxone) are strictly indicated for high-risk patients: infants <3 months, adults ≥50 years with suspected atherosclerosis (risk of endovascular grafting/mycotic aneurysm), immunocompromised hosts (HIV, sickle cell disease, malignancy), or severe sepsis.
• Shigella (S. sonnei, S. flexneri, S. dysenteriae): Extremely low infectious inoculum (10 to 100 organisms). Transmitted readily via fecal-oral route in child care centers and among men who have sex with men (MSM). Causes hallmark severe tenesmus, high spiking fevers, and frequent, small-volume stools laden with blood, mucus, and sloughed mucosa.
• Giardia duodenalis (G. lamblia): Flagellated protozoan acquired by drinking untreated wilderness stream/well water or from child care exposures. Inhabits the duodenum and upper jejunum, causing epithelial brush border blunting without mucosal ulceration. Clinical hallmark: persistent watery, greasy, foul-smelling, floating stools accompanied by profound sulfurous belching, bloating, flatulence, and epigastric cramping lasting >1 to 2 weeks. Treated with oral tinidazole (2 g single dose) or oral metronidazole (250 to 500 mg TID for 5 to 7 days).

---

Clinical Indications for Diagnostic Stool Testing

Most acute, mild-to-moderate watery diarrhea in healthy outpatients requires zero laboratory evaluation. Unnecessary stool testing exposes healthcare systems to significant costs without altering clinical management.

When Diagnostic Testing IS Indicated (IDSA / ACG Guidelines)

Stool evaluation should be performed promptly when any of the following clinical criteria are present:

1. Severe Illness: High fever (oral temperature ≥38.5°C / 101.3°F), severe volume depletion, orthostatic hypotension, or signs of systemic sepsis.
2. Dysentery / Bloody Diarrhea: Frank hematochezia, visible rectal blood, or bloody mucoid stools.
3. Prolonged Symptom Duration: Diarrhea persisting longer than 7 days without clinical improvement.
4. Vulnerable / High-Risk Hosts: Elderly patients (age ≥65 years), infants, severe underlying medical comorbidities (cirrhosis, end-stage renal disease, severe congestive heart failure), or immunocompromised hosts (HIV/AIDS with CD4 <200, solid organ transplant, active systemic chemotherapy, biologic immunosuppressive agents).
5. Public Health & Occupational Concerns: Commercial food handlers, healthcare workers, and daycare staff or attendees.
6. Recent Hospitalization or Antibiotic Exposure: Symptoms developing ≥48 hours after hospital admission or within 90 days of antimicrobial therapy (mandates testing for C. difficile).

Diagnostic Modalities

• Multiplex Molecular GI Stool PCR (GI Pathogen Panel): Rapid, highly sensitive and specific syndromic nucleic acid amplification test (NAAT) detecting 15 to 22 common bacterial, viral, and parasitic targets within 1 to 4 hours. Preferred initial test in hospitalized or severely ill patients.
• Conventional Stool Bacterial Culture: Detects Salmonella, Shigella, Campylobacter, and Yersinia. Requires specific request for Sorbitol-MacConkey (SMAC) agar to identify E. coli O157:H7 (which fails to ferment sorbitol, appearing as clear/white colonies).
• Fecal Leukocytes and Fecal Lactoferrin: Qualitative or quantitative surrogate markers of mucosal inflammation that differentiate inflammatory dysentery from secretory or functional diarrhea.
• Stool Ova and Parasites (O&P) Microscopic Exam: Recommended primarily for diarrhea persisting >14 days, wilderness water exposure, travel to endemic developing nations, or persistent diarrhea in immunocompromised hosts. Three separate stool specimens collected on consecutive days optimize diagnostic sensitivity.

---

Shiga Toxin-Producing E. Coli (STEC) & Hemolytic Uremic Syndrome (HUS)

[!CAUTION] CRITICAL CLINICAL PEARL: CONTRAINDICATION TO ANTIMICROBIALS & ANTIMOTILITY AGENTS IN STEC In any patient presenting with acute bloody diarrhea where Shiga toxin-producing Escherichia coli (STEC / E. coli O157:H7) is confirmed or strongly suspected, ANTIMICROBIAL THERAPY AND ANTIMOTILITY AGENTS (LOPERAMIDE) ARE STRICTLY CONTRAINDICATED! Administration of antibiotics induces bacterial stress and triggers prophage lytic activation, causing massive, explosive release of preformed Shiga toxins (Stx1 and Stx2). This dramatically increases the incidence and severity of Hemolytic Uremic Syndrome (HUS) by up to 10-fold. Antimotility agents paralyze intestinal peristalsis, prolonging gut mucosal contact with Shiga toxins and facilitating systemic toxin absorption.

Pathophysiology of Hemolytic Uremic Syndrome

• STEC is contracted through ingestion of undercooked ground beef, unpasteurized milk or apple cider, fecally contaminated water, or petting zoos.
• Symptoms begin after a 2- to 8-day incubation period as non-bloody watery diarrhea with severe, agonizing, crampy abdominal pain. Within 24 to 72 hours, the stool turns grossly bloody (dysentery) in >90% of patients. A prominent clinical hallmark is the absence of high fever (patients are typically afebrile or have low-grade temperature <38.0°C), distinguishing STEC from Shigella or Campylobacter.
• Systemic absorption of Shiga toxins (predominantly Stx2) leads to toxin binding to globotriaosylceramide (Gb3) receptors, which are densely expressed on vascular endothelial cells in renal glomeruli and the cerebral microvasculature.
• Endothelial cell apoptosis and detachment expose thrombogenic subendothelial collagen, triggering widespread platelet microthrombi formation, capillary lumen narrowing, mechanical erythrocyte fragmentation, and glomerular ischemic necrosis.

The Classic HUS Triad

HUS typically develops 5 to 10 days after the onset of diarrhea (often just as gastrointestinal symptoms are improving):

1. Microangiopathic Hemolytic Anemia (MAHA): Severe normocytic anemia with abundant schistocytes (helmet cells) on peripheral blood smear, elevated serum lactate dehydrogenase (LDH), indirect hyperbilirubinemia, reticulocytosis, and undetectable serum haptoglobin; direct Coombs test is negative.
2. Thrombocytopenia: Platelet consumption within microvascular thrombi, typically dropping platelets to <50,000/mcL. PT/INR and aPTT are normal (distinguishing HUS from disseminated intravascular coagulation [DIC]).
3. Acute Kidney Injury (AKI): Oliguria or anuria, elevated serum creatinine, microscopic hematuria, and proteinuria.

Evidence-Based Management of STEC Infection

• Immediate Discontinuation / Avoidance of Antibiotics and Loperamide.
• Aggressive Early Intravenous Isotonic Fluid Resuscitation: Maintaining vigorous intravascular volume expansion during the initial diarrheal phase preserves renal capillary perfusion and has been shown to significantly attenuate the development of anuric renal failure and permanent dialysis dependence.
• Close Outpatient or Inpatient Surveillance: Daily monitoring of complete blood count (CBC with differential and platelet count), serum creatinine, BUN, electrolytes, and urine output until 7 to 10 days after diarrhea onset.

---

Clostridioides Difficile Infection (CDI)

Clostridioides difficile (formerly Clostridium difficile) is an anaerobic, spore-forming, toxin-producing Gram-positive rod that represents the leading cause of healthcare-associated and antibiotic-associated infectious diarrhea.

Risk Factors & Pathogenesis

• Antimicrobial Exposure: The single greatest risk factor. Exposure to broad-spectrum antibiotics within the preceding 90 days disrupts the normal colonic microbial barrier (loss of colonization resistance). Highest risk agents include: fluoroquinolones, clindamycin, 3rd- and 4th-generation cephalosporins, carbapenems, and broad-spectrum beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam).
• Host Factors: Age ≥65 years, recent hospitalization or skilled nursing facility residency, gastrointestinal surgery, underlying inflammatory bowel disease, immunocompromised status, and chronic acid suppression with proton pump inhibitors (PPIs).
• Toxins: Pathogenic strains produce two potent exotoxins:
  • Toxin A (Enterotoxin): Causes mucosal brush border disruption, fluid secretion, and mucosal inflammation.
  • Toxin B (Cytotoxin): 10 times more potent than Toxin A; depolymerizes host cell actin filaments, causing colonocyte apoptosis, detachment, pseudomembrane formation, and mucosal necrosis.

Diagnostic Testing: Principles & Pitfalls

• Test Selection Rule: Stool testing should ONLY be performed on patients with unexplained, new-onset loose or liquid stools (≥3 unformed stools in 24 hours). Testing formed stool is strictly contraindicated because asymptomatic colonization occurs in up to 10% to 20% of hospitalized patients and up to 50% of long-term care residents. Never perform a "test of cure" following treatment, as stool PCR tests remain positive for months despite clinical cure.
• Diagnostic Algorithm:
  • Two-Step Algorithm: Initial screening with Glutamate Dehydrogenase (GDH) antigen (highly sensitive marker of C. diff presence) combined with Toxin A/B Enzyme Immunoassay (EIA) (highly specific for active toxin production).
  • If both are positive: Confirmed active CDI.
  • If GDH is negative and Toxin EIA is negative: CDI excluded.
  • If discordant (GDH positive, Toxin EIA negative): Reflex to Nucleic Acid Amplification Test (NAAT / PCR) to determine whether a toxigenic gene (tcdB) is present, differentiating active low-toxin disease from asymptomatic colonization in clinical context.

Severity Stratification & First-Line Guideline Pharmacotherapy

According to official Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines:

[!IMPORTANT] Why Fidaxomicin is Preferred over Vancomycin & Why Metronidazole is Deprecated:

• Fidaxomicin is a narrow-spectrum macrocyclic antibiotic that selectively inhibits bacterial RNA polymerase. Because it specifically targets C. diff while sparing normal gut commensal anaerobes (especially Bacteroides species), it preserves colonization resistance and results in an ~50% lower rate of recurrent CDI compared to vancomycin.
• Oral Vancomycin remains an excellent, accessible alternative. Note: Intravenous vancomycin is completely ineffective for CDI because it is not excreted into the intestinal lumen; it must be administered orally.
• Oral Metronidazole is no longer recommended for initial episodes due to clear clinical trial evidence demonstrating significantly lower clinical cure rates and higher rates of treatment failure and disease recurrence compared to vancomycin and fidaxomicin. It is only considered if fidaxomicin and vancomycin are unavailable.

Management of Recurrent CDI

• First Recurrence:
  • If oral vancomycin was used for the initial episode: Prescribe Oral Fidaxomicin 200 mg BID for 10 days (or extended-pulsed fidaxomicin).
  • If fidaxomicin was used initially: Prescribe a tapered and pulsed Oral Vancomycin regimen (e.g., 125 mg QID x 10-14d, then BID x 7d, then once daily x 7d, then every 2-3 days for 2-8 weeks).
  • Adjunctive Monoclonal Antibody: Bezlotoxumab (single IV infusion 10 mg/kg), a human monoclonal antibody targeting C. diff Toxin B, can be co-administered with standard antibiotics to prevent further recurrences in patients at high risk (age ≥65, immunocompromised, severe initial CDI).
• Second or Subsequent Recurrence (≥2 Recurrences):
  • Fecal Microbiota Transplantation (FMT) or FDA-approved live biotherapeutic products (e.g., fecal microbiota spores, Firmicutes spores / SER-109 / VOWST) are standard of care, restoring gut microbiome biodiversity with cure rates exceeding 85% to 90%.

---

Traveler's Diarrhea (TD) & Geographic Antimicrobial Stewardship

Traveler's diarrhea is defined as the passage of ≥3 unformed stools in 24 hours accompanied by at least one enteric symptom (abdominal cramps, nausea, vomiting, fever, fecal urgency) occurring in an individual traveling from an industrialized country to a resource-limited destination.

Etiology & Geographic Distribution

• Bacterial Pathogens (80% to 90%): Enterotoxigenic E. coli (ETEC) is the most common cause worldwide (50% to 80% of bacterial cases), utilizing plasmid-encoded heat-labile (LT) and/or heat-stable (ST) toxins to hyperactivate enterocyte adenylate and guanylate cyclases. Other bacterial culprits include Campylobacter jejuni, Shigella, and Salmonella.
• Geographic Resistance Patterns: In South Asia and Southeast Asia (India, Thailand, Nepal), fluoroquinolone-resistant Campylobacter exceeds 80% to 90%, rendering ciprofloxacin completely ineffective. In Latin America, the Caribbean, and Africa, ETEC and other pathogens remain moderately susceptible to fluoroquinolones.

Clinical Staging & Stepwise Management

1. Mild TD (Tolerable, does not interfere with planned activities):
   • Pharmacotherapy: Oral Rehydration Therapy alone. Loperamide or bismuth subsalicylate (Pepto-Bismol, 524 mg chewable tablets every 30 to 60 minutes, max 8 doses/day) may be used for symptomatic relief. Antibiotics are NOT recommended.
2. Moderate TD (Distressing, interferes with planned activities):
   • Pharmacotherapy: Loperamide as monotherapy or combined with a single dose of an antibiotic.
3. Severe TD (Incapacitating, prevents all activity, or any gross dysentery / bloody stools):
   • First-Line for Dysentery, Bloody Stools, High Fever, or Travel to South/Southeast Asia:
     • Oral Azithromycin: 1,000 mg as a single oral dose, OR 500 mg orally once daily for 3 days.
     • Azithromycin is the gold-standard drug of choice for traveler's diarrhea in Southeast Asia, overcoming fluoroquinolone resistance and effectively treating invasive Campylobacter and Shigella.
   • Alternative for Non-Dysenteric Watery Diarrhea in Latin America / Africa:
     • Oral Ciprofloxacin (750 mg single dose or 500 mg BID x 3 days) or Levofloxacin (500 mg single dose).
     • Oral Rifaximin (200 mg TID for 3 days): Non-absorbable rifamycin derivative. Highly effective for non-invasive ETEC watery diarrhea, but strictly contraindicated if fever or bloody stools are present because it lacks systemic bioavailability and fails to treat invasive pathogens (Campylobacter, Salmonella, Shigella).

---

Oral Rehydration Therapy & Antimotility Safety Rules

Oral Rehydration Solution (ORS) Science

• The cornerstone of all diarrheal management is fluid and electrolyte replacement. Intestinal fluid absorption depends on the sodium-glucose cotransporter (SGLT-1) located on the brush border membrane of mature small intestinal villus enterocytes.
• Even during profound toxin-mediated secretory diarrhea (e.g., cholera, ETEC), where cyclic nucleotides shut down electroneutral sodium chloride absorption and stimulate massive chloride secretion, SGLT-1 remains fully operational.
• Coupling 1 molecule of sodium to 1 molecule of glucose allows active cotransport into enterocytes, generating an osmotic gradient that pulls water from the gut lumen into the circulation.
• WHO Reduced-Osmolarity ORS Formulation (Osmolarity 245 mOsm/L):
  • Sodium: 75 mEq/L
  • Glucose: 75 mmol/L (13.5 g/L)
  • Potassium: 20 mEq/L
  • Chloride: 65 mEq/L
  • Citrate: 10 mmol/L (2.9 g/L)
• Clinical Pitfall: Commercial sodas, fruit juices, and sports drinks have excessive osmolarity (>400-600 mOsm/L) and low sodium concentrations (<20 mEq/L), which exacerbate osmotic diarrhea and can precipitate hyponatremia.

Loperamide: Clinical Mechanism, Dosing & Absolute Contraindications

• Mechanism of Action: Peripheral mu-opioid receptor agonist in the myenteric (Auerbach) plexus of the intestinal wall. It slows circular and longitudinal intestinal peristalsis, increases gastrointestinal transit time, enhances fluid and electrolyte mucosal absorption, and increases anal sphincter resting tone.
• Adult Dosing: Initial dose of 4 mg orally, followed by 2 mg after each unformed stool (maximum OTC dose: 8 mg/day; maximum prescription dose: 16 mg/day) for no more than 48 hours.
• Absolute Contraindications:
  1. Bloody diarrhea (gross hematochezia / dysentery);
  2. High fever (temperature ≥38.5°C / 101.3°F) or signs of systemic toxicity;
  3. Confirmed or suspected Shiga toxin-producing E. coli (STEC) (precipitates severe HUS);
  4. Active Clostridioides difficile infection (precipitates toxic megacolon and bowel perforation).